Latham & Watkins LLP represents Vistagen in the offering. Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for...
Vistagen’s US$100 Million Underwritten Offering
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
e.l.f. Beauty’s US$355 Million Acquisition of Naturium
Latham & Watkins advises e.l.f. Beauty in its acquisition of Naturium. e.l.f. Beauty (NYSE: ELF) has announced it has signed a definitive agreement to acquire Naturium,...
Heron Therapeutics’ Capital Credit Facility Agreement With Hercules Capital
Latham & Watkins advises on Heron Therapeutics’ working capital credit facility. Heron Therapeutics, Inc. (Heron), a commercial-stage biotechnology company focused on improving the lives of patients...
MindMed’s Senior Secured Credit Facility With K2 HealthVentures LLC
Latham & Watkins advises MindMed in growth financing with K2 HealthVentures. Mind Medicine Inc. (MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
ODDITY Tech’s $424 Million IPO
Herzog Fox & Neeman and Latham & Watkins LLP are advising ODDITY Tech Ltd., while Davis Polk & Wardwell and Goldfarb Gross Seligman & Co. are...
RadNet’s $259.2 Million Common Stock Public Offering
Sheppard Mullin represented RadNet, and Latham & Watkins represented the underwriters. RadNet, Inc. (NASDAQ: RDNT) has announced the closing of its underwritten public offering of 8,711,250 shares...
Guardant Health’s Upsized Public Offering of Common Stock
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...
Ironwood Pharmaceuticals’ $1 Billion Acquisition of VectivBio Holding
Advestra and Latham & Watkins advise Ironwood. Homburger AG serves as legal and tax advisor to VectivBio on the transaction. Goodwin advises Centerview Partners. VectivBio Holding...
4D Molecular Therapeutics’ $120 Million Common Stock Offering
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...